- RecruitingPHASE2
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
This study tests a new drug called bexmarilimab alongside a standard treatment (azacitidine) for adults newly diagnosed with higher-risk myelodysplastic syndromes (MDS). Researchers want to find the safest and most effective dose, and see if combining these treatments helps manage this blood condition better than standard treatment alone.
For: Higher Risk Myelodysplastic SyndromesUnited States · Czechia · Finland - RecruitingPhase I and Phase II (Integrated)- Other
A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02)
This study is for people with a type of blood disorder called higher-risk myelodysplastic syndrome (MDS) who haven't had treatment yet. It tests a new drug called ALX148 with an existing medicine, azacitidine, to see if it's safe and helps improve the condition.
For: Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been · treated for their diseaseSpain - Active not recruitingPHASE3
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
This study looks at a new drug, venetoclax, combined with existing treatment, azacitidine, for adults with a type of blood disorder called higher-risk Myelodysplastic Syndrome (MDS). It aims to see if this combination is safe and effective compared to azacitidine alone.
For: Myelodysplastic Syndrome (MDS)United States · Australia · Austria - Active not recruitingPHASE3
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
This study looks at a new drug (AG-120) combined with a standard treatment (azacitidine) for adults newly diagnosed with a specific type of acute myeloid leukaemia (AML) that has a particular gene change (IDH1 mutation). It compares this combination to azacitidine alone to see if it works better.
For: Newly Diagnosed Acute Myeloid Leukemia (AML) · Untreated AML · AML Arising From Myelodysplastic Syndrome (MDS)United States · Australia · Austria - Not yet recruitingPhase II
A trial to evaluate the safety and efficacy of treatment with azacitidine in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
This study looks at a new drug, azacitidine, for non-obstructive hypertrophic cardiomyopathy (nHCM), a common heart condition. It aims to see if azacitidine is safe and effective in treating nHCM, which currently has limited direct treatments.
For: Symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM)United Kingdom · Northern Ireland - RecruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies
This study is looking at a new drug, BLU-263, for a rare blood cancer called Advanced Systemic Mastocytosis. It will be tested alone and with another drug, azacitidine, to see how safe it is and how well it works.
For: Advanced Systemic MastocytosisBelgium · Spain · France - RecruitingPHASE3
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
This study looks at a new drug called venetoclax for children, teenagers, and young adults with acute myeloid leukaemia (AML) that has come back. It aims to see if adding venetoclax to standard chemotherapy can help improve their chances of survival.
For: Acute Myeloid LeukemiaUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
This study is testing a new drug, IMGN632, for adults with a type of blood cancer called Acute Myeloid Leukemia (AML). It's looking at whether IMGN632 is safe and effective when given alone or with other common AML treatments.
For: Acute Myeloid LeukemiaUnited States · France · Germany - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - Active not recruitingPHASE3
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
This study looks at a new drug, galinpepimut-S, for people with a type of blood cancer called Acute Myeloid Leukaemia (AML) who are in remission. It compares the new drug to standard treatments to see if it helps people live longer.
For: Acute Myeloid LeukemiaUnited States · France · Germany - RecruitingPHASE3
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
This study looks at two medicines, ivosidenib and azacitidine, for a blood condition called myelodysplastic syndromes (MDS). It's for people with a specific gene change (IDH1 mutation) who haven't had certain treatments before. The aim is to see which medicine works best.
For: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS)United States · Australia · Brazil - Active not recruitingPHASE2
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
This study looks at treating certain blood cancers with a drug called azacitidine. Researchers want to see if adding lenalidomide or vorinostat makes azacitidine work better. It’s for adults with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML).
For: Chronic Myelomonocytic Leukemia · Chronic Myelomonocytic Leukemia-1 · Chronic Myelomonocytic Leukemia-2United States · Canada - RecruitingPHASE2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This study helps doctors find the best treatments for people with certain blood cancers like leukaemia. It uses special tests on blood and bone marrow to match patients with personalised treatments or standard care, aiming to improve how cancer treatments are chosen.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - RecruitingPHASE2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This study looks at new ways to treat a serious type of blood cancer called AML in people aged 18-59. It compares standard treatment with newer drug combinations to see if they work better at shrinking the cancer.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - Active not recruitingPHASE1
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
This study looks at a new drug called cusatuzumab, given with standard treatments, for people newly diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML). It aims to find out how safe these treatments are together and if people can tolerate them well.
For: Leukemia, Myeloid, AcuteUnited States · Canada · Germany - Active not recruitingPHASE1, PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
This study looks at a new drug, bexmarilimab, alongside standard treatments for certain blood cancers like leukaemia and MDS. We want to find a safe dose and see how well it works to help patients.
For: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic SyndromesUnited States · Finland · United Kingdom - RecruitingPHASE2, PHASE3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
This study is testing new ways to treat certain blood cancers, like some types of leukaemia and myelodysplastic syndromes. Researchers are looking at a new drug, ASTX030, sometimes with another drug called venetoclax, to see if it's safe and works better than current treatments.
For: Myelodysplastic Syndromes · Acute Myeloid Leukemia · Myelodysplastic Syndrome/NeoplasmUnited States · Canada · Czechia - Active not recruitingPHASE1
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
This study looks at a new combination treatment, venetoclax and azacitidine, for people in the UK with a higher-risk type of blood cancer called Myelodysplastic Syndromes (MDS) who haven't had treatment before. It's an early-stage study to find the best dose.
For: Myelodysplastic Syndromes (MDS)United States · Australia · Canada - RecruitingPHASE1, PHASE2
A Study of BGB-11417 in Participants With Myeloid Malignancies
This study is looking at a new drug, BGB-11417, for certain blood cancers like acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Researchers want to see if it's safe, what dose works best, and if it helps people, either alone or with another treatment called azacitidine.
For: Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative NeoplasmUnited States · Australia · China - Active not recruitingPHASE1, PHASE2
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukaemia (AML) in adults. It's for people who can't have standard, strong chemotherapy. We're testing two combinations of new medicines with an existing drug (azacitidine) to see how safe and effective they are.
For: Leukemia, Myeloid, AcuteUnited States · Australia · Belgium